为肝细胞癌武装 GPC3 CAR-T 细胞：多少才足够，下一步是什么？
Armouring GPC3 CAR T cells for hepatocellular carcinoma: how much is enough and what comes next?
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
调节肠道菌群对肝癌免疫治疗的潜在影响
英文原题：Potential Effects of Regulating Intestinal Flora on Immunotherapy for Liver Cancer.
查看英文原题
Potential Effects of Regulating Intestinal Flora on Immunotherapy for Liver Cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
肠道菌群在肝癌的发生发展中发挥重要作用，影响常规抗肿瘤治疗的疗效及副作用。近年来，肝癌的免疫治疗成为无手术指征的晚期肝癌患者的姑息性治疗方法，代表性药物包括免疫检查点抑制剂、调节剂、肿瘤疫苗和细胞免疫治疗等。由于肿瘤的异质性，免疫治疗对肝癌的效果各异。肠道菌群可通过调节宿主免疫，影响肝癌免疫治疗的疗效及副作用。因此，应用益生菌、益生元、抗生素和粪便移植等手段干预肠道菌群，有望成为辅助肝癌免疫治疗的重要手段。本文综述了讨论肠道菌群与肝癌免疫治疗关系的文献，进一步阐明肠道菌群与肝癌免疫治疗之间的潜在关系。
展开英文摘要原文
The intestinal flora plays an important role in the occurrence and development of liver cancer, affecting the efficacy and side effects of conventional antitumor therapy. Recently, immunotherapy for liver cancer has been a palliative treatment for patients with advanced liver cancer lacking surgical indications.
Representative drugs include immune checkpoint inhibitors, regulators, tumor vaccines, and cellular immunotherapies. The effects of immunotherapy on liver cancer vary because of the heterogeneity of the tumors. Intestinal flora can affect the efficacy and side effects of immunotherapy for liver cancer by regulating host immunity.
Therefore, applying probiotics, prebiotics, antibiotics, and fecal transplantation to interfere with the intestinal flora is expected to become an important means of assisting immunotherapy for liver cancer. This article reviews publications that discuss the relationship between intestinal flora and immunotherapy for liver cancer and further clarifies the potential relationship between intestinal flora and immunotherapy for liver cancer.
论文信息
- 作者
- Yan X、Bai L、Qi P、Lv J、Song X、Zhang L
- 单位
- The First Clinical Medical College, Lanzhou University, Lanzhou 730000, China.China
- 文献类型
- 综述
- 期刊
- International journal of molecular sciences2023 Jul 13
- 原文标识
- PubMed 37511148 · DOI 10.3390/ijms241411387